selected publications
- Author Correction: ChromaFold predicts the 3D contact map from single-cell chromatin accessibility. 2025 GET IT
- EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer cell. 2024 Academic Article GET IT
- ChromaFold predicts the 3D contact map from single-cell chromatin accessibility. Nature communications. 2024 Academic Article GET IT
- Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature communications. 2024 Academic Article GET IT
- Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast cancer research : BCR. 2023 Article GET IT
- Correction: Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. 2023 GET IT
- Corrigendum to "Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer" [Steroids 76 (2011) 381-392]. 2023 GET IT
-
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.
Cancer discovery.
2023
Editorial Article
GET IT
Times cited: 8 - Tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma. The Journal of clinical investigation. 2022 Academic Article GET IT
- Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms. Frontiers in cell and developmental biology. 2022 Academic Article GET IT
- Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. Nature immunology. 2022 Academic Article GET IT
- Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in cell and developmental biology. 2022 Review GET IT
- Loss of function mutations of BCOR in classical Hodgkin lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
-
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Nature immunology.
2021
Academic Article
GET IT
Times cited: 25 -
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.
Nature.
2020
Academic Article
GET IT
Times cited: 157 -
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.
Cell.
2020
Academic Article
GET IT
Times cited: 73 -
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Cancer cell.
2020
Academic Article
GET IT
Times cited: 97 -
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL.
Nature communications.
2019
Academic Article
GET IT
Times cited: 59 -
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Cancer discovery.
2019
Academic Article
GET IT
Times cited: 88 -
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 125 -
Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells.
Biomaterials.
2018
Academic Article
GET IT
Times cited: 34 -
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Leukemia & lymphoma.
2018
Information Resource
GET IT
Times cited: 145 -
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.
Nature communications.
2017
Academic Article
GET IT
Times cited: 127 -
Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.
Science translational medicine.
2017
Academic Article
GET IT
Times cited: 48 -
Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation.
ACS biomaterials science & engineering.
2017
Academic Article
GET IT
Times cited: 17 -
Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.
Immunity.
2016
Academic Article
GET IT
Times cited: 105 -
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.
Cancer cell.
2016
Academic Article
GET IT
Times cited: 182 -
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
The Journal of clinical investigation.
2016
Academic Article
GET IT
Times cited: 132 -
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".
Nature medicine.
2016
Article
GET IT
Times cited: 7 -
Loss of BAP1 function leads to EZH2-dependent transformation.
Nature medicine.
2015
Academic Article
GET IT
Times cited: 289 -
IL10 receptor is a novel therapeutic target in DLBCLs.
Leukemia.
2015
Academic Article
GET IT
Times cited: 45 -
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
Oncogene.
2014
Academic Article
GET IT
Times cited: 35 -
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
Science translational medicine.
2014
Academic Article
GET IT
Times cited: 111 -
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Breast cancer research : BCR.
2013
Academic Article
GET IT
Times cited: 30 -
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Cancer cell.
2013
Academic Article
GET IT
Times cited: 674 -
p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth.
Endocrine-related cancer.
2013
Academic Article
GET IT
Times cited: 51 -
Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells.
Journal of immunology (Baltimore, Md. : 1950).
2012
Academic Article
GET IT
Times cited: 30 -
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.
BMC cancer.
2012
Academic Article
GET IT
Times cited: 37 -
Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer.
Steroids.
2010
Academic Article
GET IT
Times cited: 19 -
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.
Molecular and cellular biology.
2010
Academic Article
GET IT
Times cited: 88 -
Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation.
Breast cancer research and treatment.
2009
Academic Article
GET IT
Times cited: 27 -
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.
Molecular and cellular biology.
2008
Academic Article
GET IT
Times cited: 52 -
TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.
Experimental cell research.
2007
Academic Article
GET IT
Times cited: 110 -
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
Oncogene.
2006
Academic Article
GET IT
Times cited: 39